Medical Xpress July 31, 2021
Mike Cummings,

Access to clinical-trial data helps doctors make informed prescribing decisions and promotes good science, but a new study co-authored by Yale researchers reveals that few pharmaceutical companies are fully transparent about the data behind the products they develop. The study also shows that large companies are far more transparent than smaller ones.

The study, published in The BMJ Open (British Medical Journal), assessed the data-sharing practices of 42 for clinical trials of 40 novel drugs and 22 biologics—products, such as vaccines, derived from living organisms—approved by the U.S. Food and Drug Administration in 2016 and 2017. The evaluation was performed using the Good Pharma Scorecard, a tool developed by researchers at Yale, Stanford, and Bioethics International which consists...

Today's Sponsors

Canton & Company

Today's Sponsors

Curation Health

Today's Sponsor


Topics: Biotechnology, Pharma, Pharma / Biotech, Provider, Survey / Study, Trends
Rune Labs Lands $22.8M to for Neurology Precision Medicine Platform
Getting strategic about new-product submissions in the pharma industry
Venture firms warn R&D funding for new drugs will 'drop off a cliff' if Dem bill approved
Contentious report suggests safety net hospitals leveraging discounts to pocket strong gains from cancer drugs
Adrian Cheng Moves Deeper Into Healthcare Industry With Artisan Merger Of Prenetics At $1.2 Bln Valuation